Our Mission
Freenome is an early cancer detection company developing blood-based screening tests to detect cancer when it is most treatable. The company's Personalized Cancer Detection approach combines multiomics, artificial intelligence and machine learning to develop screening tests tailored to the biology of individual cancers and the needs of specific patient populations.
Freenome’s first commercial-stage test, SimpleScreen™ CRC, is an FDA-approved blood-based screening test for colorectal cancer in adults 45 and older who are at average risk for the disease. Beyond colorectal cancer, Freenome continues to advance a pipeline of non-invasive single-and multi-cancer screening tests across additional cancer indications, in pursuit of its mission to make cancer screening more accessible and increase participation.